About 10,743 results

ALLMedicine™ Alzheimer Disease Center

Research & Reviews  3,945 results

A Novel Selective PKR Inhibitor Restores Cognitive Deficits and Neurodegeneration in Al...
The Journal of Pharmacology and Experimental Therapeutics; Lopez-Grancha M, Bernardelli P et. al.

Sep 18th, 2021 - In Alzheimer disease (AD), the double-strand RNA-dependent kinase protein kinase R (PKR )/EIF2AK2 is activated in brain with increased phosphorylation of its substrate eukaryotic initiation factor 2α (eIF2α). AD risk-promoting factors, such as Apo...

Falls: a marker of preclinical Alzheimer disease: a cohort study protocol.
BMJ Open; Bollinger RM, Keleman A et. al.

Sep 17th, 2021 - Progression to symptomatic Alzheimer disease (AD) occurs slowly over a series of preclinical stages. Declining functional mobility may be an early indicator of loss of brain network integration and may lead to an increased risk of experiencing fal...

The Role of Orexin in Alzheimer Disease: From Sleep-wake Disturbance to Therapeutic Tar...
Neuroscience Letters; Gao F, Liu T et. al.

Sep 17th, 2021 - Accumulating evidence has shown that sleep disturbance is a common symptom in Alzheimer's disease (AD), which is regarded as a modifiable risk factor for AD. Orexin is a key modulator of the sleep-wake cycle and has been found to be dysregulated i...

Peripheral and central immune system crosstalk in Alzheimer disease - a research prospe...
https://doi.org/10.1038/s41582-021-00549-x 10.2174/1567205016666190321154618 10.1007/s12035-018-1092-y 10.1111/imm.12922 10.1111/imcb.12301 10.1016/j.trci.2018.06.014 10.1016/j.exger.2017.12.019 10.1093/gerona/glr261 10.1111/jgs.12739 10.3233/JAD-2009-1126 10.1097/00002093-199809000-00016 10.1016/j.neurobiolaging.2006.08.012 10.3233/JAD-2010-101671 10.1016/j.biopsych.2010.06.012 10.1136/jnnp-2017-316201 10.1016/j.jalz.2018.02.014 10.1093/gerona/gls187 10.1002/ana.10265 10.1001/archneur.61.5.668 10.1212/01.wnl.0000263217.36439.da 10.1212/WNL.59.3.371 10.1212/01.WNL.0000073620.42047.D7 10.1212/WNL.0000000000000665 10.1001/jama.292.18.2237 10.1001/jamanetworkopen.2018.3597 10.1001/jamaneurol.2017.1658 10.3389/fnagi.2019.00025 10.1097/01.psy.0000238451.22174.92 10.1212/WNL.0b013e3181d7b45b 10.1212/01.wnl.0000257815.20548.df 10.1016/j.bbi.2011.07.240 10.1016/j.bbi.2020.01.006 10.3233/JAD-180469 10.1136/jnnp-2018-319148 10.3233/JAD-2010-100921 10.3233/JAD-150042 10.1371/journal.pone.0064971 10.1016/j.neurobiolaging.2005.10.007 10.1016/j.jalz.2019.03.007 10.1016/j.imlet.2007.09.002 10.1007/s12035-014-8657-1 10.1016/j.neurobiolaging.2019.09.020 10.1016/j.bbi.2017.01.020 10.3233/JAD-170602 10.1016/j.jalz.2018.02.018 10.1002/alz.12399 10.1186/s13024-018-0293-1 10.1186/s12974-020-01806-4 10.1002/ana.25159 10.1038/ni1033 10.2741/A831 10.1002/ana.25678 10.1212/WNL.0b013e318225ae07 10.1042/BST0390945 10.1001/jama.2010.1553 10.1016/S1474-4422(15)70016-5 10.1136/jnnp.74.6.788 10.1212/WNL.0b013e3181b6bb95 10.1016/S1473-3099(21)00144-4 10.1186/s40478-018-0592-3 10.1371/journal.pone.0030525 10.1002/acn3.51109 10.1126/scitranslmed.aav6221 10.1016/j.neurobiolaging.2018.12.019 10.1016/j.jalz.2011.03.003 10.3233/JAD-170887 10.1016/j.arr.2019.01.002 10.1093/brain/awy079 10.1186/s40478-019-0795-2 10.3233/JAD-2009-1015 10.1016/j.jneuroim.2011.11.005 10.1007/s11481-015-9612-2 10.1016/j.bbi.2010.12.004 10.1038/s41598-019-45433-3 10.3233/JAD-2010-091696 10.3389/fimmu.2017.00783 10.1016/j.neurobiolaging.2014.08.008 10.1038/s41586-019-1895-7 10.1093/brain/awt210 10.1159/000486200 10.3233/JAD-180176 10.1038/s41598-017-13601-y 10.1016/j.neurobiolaging.2016.08.019 10.1038/s42255-021-00348-0 10.1021/acschemneuro.9b00333 10.1016/S1566-0702(00)00220-4 10.1038/ni.3666 10.1038/s41586-018-0023-4 10.15252/embj.2018101064 10.1038/nature10357 10.1016/j.neuron.2006.01.022 10.1038/nm1555 10.1038/nm1781 10.1523/JNEUROSCI.0299-11.2011 10.1084/jem.20150478 10.1084/jem.20150479 10.3233/JAD-130539 10.1038/nm.3913 10.1016/j.neurobiolaging.2013.12.026 10.1038/s41593-018-0329-4 10.1038/nrneurol.2017.188 10.1371/journal.pone.0053455 10.1016/j.expneurol.2007.01.003 10.1172/JCI90606 10.1038/nature11729 10.1016/0304-3940(92)90071-E 10.1159/000022076 10.1016/j.nbd.2009.01.006 10.1016/j.nbd.2017.02.010 10.1016/0896-6273(94)90362-X 10.1038/ni.2913 10.1038/nature25158 10.1038/s41586-018-0543-y 10.1038/s41586-019-1769-z 10.1007/978-1-4939-9658-2_21 10.1073/pnas.1525466113 10.1186/s40478-015-0251-x 10.1016/S0165-5728(01)00496-9 10.1016/0304-3940(88)90690-8 10.1016/S0197-4580(88)80079-4 10.1186/s12974-015-0317-5 10.1073/pnas.0506209103 10.4049/jimmunol.1200947 10.1016/j.nbd.2008.12.015 10.1016/j.nbd.2006.03.008 10.4049/jimmunol.1003953 10.1093/brain/awv408 10.1038/ncomms8967 10.1093/brain/aww270 10.1038/srep41802 10.1038/s41422-019-0216-x 10.1038/nm.4106 10.1038/srep30028 10.1084/jem.20182386 10.1002/ana.22191 10.1038/s41380-020-0856-8 10.3233/JAD-200492 10.1093/aje/kwz030 10.1038/ni.3102 10.1016/j.bbadis.2014.04.012 10.1038/nrneurol.2017.111 10.1016/j.trci.2015.06.004 10.1111/bpa.12763 10.1007/s00259-019-04462-w 10.1016/j.bbi.2020.10.025 10.1001/jama.2017.3090 10.1016/j.immuni.2017.06.006 10.1038/s41586-021-03734-6 10.1371/journal.pone.0038013 10.1016/j.mcn.2020.103568 10.1038/s41577-018-0051-1 10.1016/j.it.2020.02.002 10.3233/JAD-2006-9S330 10.1212/01.wnl.0000313813.48505.86 10.1038/s41588-018-0311-9
Nature Reviews. Neurology; Bettcher BM, Tansey MG et. al.

Sep 16th, 2021 - Dysregulation of the immune system is a cardinal feature of Alzheimer disease (AD), and a considerable body of evidence indicates that pathological alterations in central and peripheral immune responses that change over time. Considering AD as a s...

see more →

Guidelines  6 results

ACR Appropriateness Criteria® Dementia.
Journal of the American College of Radiology : JACR; , Moonis G et. al.

May 7th, 2020 - Degenerative disease of the central nervous system is a growing public health concern. The primary role of neuroimaging in the workup of patients with probable or possible Alzheimer disease has typically been to exclude other significant intracran...

Falls Risk and Alzheimer Disease: A Patient Guide.
Archives of Physical Medicine and Rehabilitation; Kahya M, Sood P et. al.

Mar 3rd, 2020 - Falls Risk and Alzheimer Disease: A Patient Guide.|2020|Kahya M,Sood P,Devos H,Krishnan S,Hirsch MA,|

Diagnostic criteria for vascular cognitive disorders: a VASCOG statement.
Alzheimer Disease and Associated Disorders; Sachdev P, Kalaria R et. al.

Mar 19th, 2014 - Several sets of diagnostic criteria have been published for vascular dementia since the 1960s. The continuing ambiguity in vascular dementia definition warrants a critical reexamination. Participants at a special symposium of the International Soc...

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cogn...
Alzheimer's & Dementia : the Journal of the Alzheimer's A... Johnson KA, Minoshima S et. al.

Jul 3rd, 2013 - Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer's Association and S...

Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the ...
Genetics in Medicine : Official Journal of the American C... Goldman JS, Hahn SE et. al.

May 18th, 2011 - Alzheimer disease is the most common cause of dementia. It occurs worldwide and affects all ethnic groups. The incidence of Alzheimer disease is increasing due, in part, to increased life expectancy and the aging baby boomer generation. The averag...

see more →

Drugs  5 results see all →

News  341 results

Mild Cognitive Impairment with Lewy Bodies or Alzheimer’s Disease and Risk of Progression to Dementia

Apr 26th, 2021 - Takeaway Patients with mild cognitive impairment (MCI) and clinical characteristics of dementia with Lewy bodies (DLB) had a worse prognosis than MCI-Alzheimer’s disease (MCI-AD), with an increased annual risk of transition from MCI to dementia. M...

TDP-43 Protein Declines Years Before Death in Alzheimer's

Nov 9th, 2020 - Brain levels of TAR DNA binding protein 43 (TDP-43), a key factor in the neurodegeneration that occurs with Alzheimer's disease, begin declining nearly two decades prior to the end of life and show an independent effect on the rate of hippocampal ...

Fast Five Quiz: Alzheimer Disease Management

Aug 19th, 2020 - Alzheimer disease is a chronic, neurodegenerative disorder of the aging population that results in progressive cognitive and behavioral dysfunction. Afflicting more than 6 million Americans and more than 8 million Europeans, Alzheimer disease is t...

Fast Five Quiz: Alzheimer Disease Management

Aug 19th, 2020 - Answer 2/5 Which of the following has been shown to achieve the highest levels of cognitive and functional abilities in patients with Alzheimer disease? Your peers chose: Early diagnosis and treatment 0% Antidepressants 0% Loop diuretics and CCBs ...

Fast Five Quiz: Alzheimer Disease Management

Aug 19th, 2020 - Alzheimer disease is a chronic, neurodegenerative disorder of the aging population that results in progressive cognitive and behavioral dysfunction. Afflicting more than 6 million Americans and more than 8 million Europeans, Alzheimer disease is t...

see more →